New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Krystal Biotech, Inc.

Contributing Author

Recent Articles by Krystal Biotech, Inc.

Sep-15	Krystal Biotech Announces FDA Approval of Updated VYJUVEK Label KRYS GlobeNewswire
Sep-02	Krystal Biotech to Present at Cantor Global Healthcare Conference 2025 KRYS GlobeNewswire
Aug-21	Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer KRYS GlobeNewswire
Aug-04	Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results KRYS GlobeNewswire
Jul-29	Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 KRYS GlobeNewswire
Jul-25	Krystal Biotech Announces Approval of VYJUVEK by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa KRYS GlobeNewswire
Jul-24	Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Decollete KRYS GlobeNewswire
Jul-09	Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis KRYS GlobeNewswire
Jun-24	Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa KRYS GlobeNewswire
Jun-03	Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference KRYS GlobeNewswire
May-07	Krystal Biotech to Present at BofA Securities 2025 Health Care Conference KRYS GlobeNewswire
May-06	Krystal Biotech Announces First Quarter 2025 Financial and Operating Results KRYS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.